Zai Lab Ownership
| ZLAB Stock | USD 28.09 1.66 6.28% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Zai |
Zai Stock Ownership Analysis
About 44.0% of the company outstanding shares are owned by institutional investors. The book value of Zai Lab was at this time reported as 6.8. The company recorded a loss per share of 2.8. Zai Lab had not issued any dividends in recent years. Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China. Zai Lab operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1951 people. For more information please call the company at 86 21 6163 2588 or visit https://www.zailaboratory.com.Besides selling stocks to institutional investors, Zai Lab also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Zai Lab's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Zai Lab's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Zai Lab Quarterly Liabilities And Stockholders Equity |
|
Zai Lab Insider Trades History
Only 1.96% of Zai Lab are currently held by insiders. Unlike Zai Lab's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Zai Lab's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Zai Lab's insider trades
Zai Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Zai Lab is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zai Lab backward and forwards among themselves. Zai Lab's institutional investor refers to the entity that pools money to purchase Zai Lab's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-06-30 | 660.6 K | Fmr Inc | 2024-09-30 | 644.9 K | Superstring Capital Management Lp | 2024-09-30 | 626.9 K | Adar1 Capital Management Llc | 2024-09-30 | 532.5 K | Allianz Asset Management Ag | 2024-06-30 | 521.8 K | Cam Group Holding A/s | 2024-09-30 | 500 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 478.6 K | M&g Plc | 2024-06-30 | 437.3 K | Candriam Luxembourg S.c.a. | 2024-06-30 | 365 K | Wellington Management Company Llp | 2024-06-30 | 7.1 M | Hhg Plc | 2024-06-30 | 6.5 M |
Zai Lab Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zai Lab insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zai Lab's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zai Lab insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zai Lab Outstanding Bonds
Zai Lab issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Zai Lab uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Zai bonds can be classified according to their maturity, which is the date when Zai Lab has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Zai Lab Corporate Filings
| 15th of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zai Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zai Lab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zai Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zai Lab Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zai Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zai Lab. If investors know Zai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zai Lab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.80) | Revenue Per Share 3.647 | Quarterly Revenue Growth 0.477 | Return On Assets (0.21) | Return On Equity (0.35) |
The market value of Zai Lab is measured differently than its book value, which is the value of Zai that is recorded on the company's balance sheet. Investors also form their own opinion of Zai Lab's value that differs from its market value or its book value, called intrinsic value, which is Zai Lab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zai Lab's market value can be influenced by many factors that don't directly affect Zai Lab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zai Lab's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zai Lab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zai Lab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.